06 September, 2017
(BLPH) is its Earnings per Share or EPS. The stock carved out a 52-week low down at $0.43. This company shares are 302.54% off its target price of $4.75 and the current market capitalization stands at $43.45M.
Bellerophon Therapeutics, Inc. (BLPH) lies in the middle of a very wide and falling trend in the short term and pointed towards extra losses. Bellerophon Therapeutics, Inc. has a 12 month low of $0.43 and a 12 month high of $1.98.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bellerophon (NASDAQ: BLPH) and Pluristem (NASDAQ: PSTI) with bullish sentiments.
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. Bellerophon Therapeutics, Inc. has 36.82 million shares outstanding, and in the last trade has seen ATR around 0.09. (NASDAQ:BLPH) by 99.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
Insider trading over the last 12 months, however, paints a different picture. In the a year ago there have been a total of 23 insider trades, including 17 open market buys and 6 sells. Analysts have a mean recommendation of 1.50 on this stock.
In the transaction dated August 19, 2015, the great number of shares acquired came courtesy the President and CEO; Peacock Jonathan M added a total of 5,000 shares at an average price of $5.48, amounting to approximately $27,400. The stock is trading $1.29 its 50-day moving average by 0.11%. The insider, LUEHRING JENS, now holds 39,860 shares of BLPH.
The most recent non open market insider trade was completed by TASSE DANIEL on 06/28/2017, and was a acquisition of 25,363 shares with a final price of $0.
President and CEO, Peacock Jonathan M, purchased 20,300 common shares of Bellerophon Therapeutics, Inc.
Shares of Bellerophon Therapeutics (NASDAQ BLPH) traded up 4.42% on Tuesday, hitting $1.18. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company's stock worth $821,000 after acquiring an additional 211,111 shares in the last quarter.
Market Capitalization can be thought of as the overall price to buy the company. That puts total institutional holdings at 16,282,198 shares, according to SEC filings. Of those holders, 13 had increased positions amounting to 1.55 million shares, 4 had decreased positions amounting to 139,353 shares, and 5 holders have a held position accounting for 14.59 million shares. Finally, Susquehanna International Group LLP purchased a new stake in shares of Bellerophon Therapeutics in the second quarter worth approximately $1,316,000.
